The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
StraussH.G., HenzeA., TeichmannA.Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol.2007; 104(3): 612–616.
2.
VaseyP.A., JaysonG.C., GordonA.; Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst.2004; 96(22): 1682–1691.
3.
PfistererJ., du BoisA., WagnerU.; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Gynecol Oncol.2004; 92(3): 949–956.
4.
MinagawaY., KigawaJ., KanamoriY.Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. Gynecol Oncol.2006; 101(3): 495–498.
5.
MarkmanM., KennedyA., WebsterK., PetersonG., KulpB., BelinsonJ.Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol.2001; 19(7): 1901–1905.
6.
VorobiofD.A., RapoportB.L., ChasenM.R., CohenG.L., MahomedR., KarimeM.Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. Int J Gynecol Cancer.2003; 13(3): 287–291.
7.
KushnerD.M., ConnorJ.P., SanchezF.Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol.2007; 105(2): 358–364.
8.
VaseyP.A., AtkinsonR., ColemanR.Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer.2001; 84(2): 170–178.
9.
PölcherM., MahnerS., OrtmannO.Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer–a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep.2009; 22(3): 605–613.
10.
MoriT., HosokawaK., KinoshitaY.A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer. Int J Clin Oncol.2007; 12(3): 205–211.
11.
AokiY., SatoT., TsunekiI.Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer. Int J Gynecol Cancer.2002; 12(6): 704–709.
CohenM.R., SmetzerJ.Preparing for a damaging medication error. ISMP Medication Safety Alert!1999; 4(14).
14.
SavareseD., TaplinM.E., HalabiS., HarsV., KreisW., VogelzangN.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol.1999; 26(5)(suppl 17): 39–44.
15.
CheungY.W., CradockJ.C., VishnuvajjalaB.R., FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
16.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
KrisM.G., HeskethP.J., SomerfieldM.R.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(Suppl 1): 26–31.
21.
du BoisA., VachW., KiechleM., Cramer-GiraudU., MeerpohlH.G.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology.1996; 53(Suppl 1): 46–50.
22.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
23.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
24.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
25.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85(8): 1099–1101.
26.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
27.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
28.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
33.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
34.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
35.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
36.
AronoffG.R., BennettW.M., BernsJ.S.Drug Prescribing in Renal Failure.5th ed.Philadelphia, PA: American College of Physicians; 2007.
37.
BoyiadzisM.M., LebowitzP.F., FrameJ.N., FojoT.Hematology-Oncology Therapy.New York, NY: McGraw-Hill. 2007: 570–578.
38.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
39.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6(2): 162–176.
